Analyzing R&D Budgets: BioMarin Pharmaceutical Inc. vs Viridian Therapeutics, Inc.

Biotech R&D: BioMarin vs. Viridian's Decade of Growth

__timestampBioMarin Pharmaceutical Inc.Viridian Therapeutics, Inc.
Wednesday, January 1, 2014461543000293000
Thursday, January 1, 20156348060001002000
Friday, January 1, 2016661905000888000
Sunday, January 1, 201761075300019623000
Monday, January 1, 201869632800030421000
Tuesday, January 1, 201971500700034794000
Wednesday, January 1, 202062811600028304000
Friday, January 1, 202162879300056886000
Saturday, January 1, 2022649606000100894000
Sunday, January 1, 2023746773000159765000
Monday, January 1, 2024747184000
Loading chart...

Unleashing the power of data

A Decade of Innovation: R&D Spending in Biotech

In the ever-evolving world of biotechnology, research and development (R&D) are the lifeblood of innovation. Over the past decade, BioMarin Pharmaceutical Inc. and Viridian Therapeutics, Inc. have demonstrated contrasting approaches to R&D investment. BioMarin, a leader in the field, has consistently allocated substantial resources, with a peak in 2023 where their R&D expenses surged by approximately 62% compared to 2014. This commitment underscores their dedication to pioneering treatments.

In contrast, Viridian Therapeutics, Inc. has shown a remarkable growth trajectory in R&D spending, increasing from a modest base in 2014 to a significant rise by 2023, marking an impressive 54,000% increase. This dramatic escalation highlights Viridian's strategic pivot towards innovation.

These trends reflect broader industry dynamics, where established players and emerging companies alike are investing heavily in R&D to drive future breakthroughs.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025